Loading clinical trials...
Loading clinical trials...
A Multicenter Phase II Study, to Evaluate the Predictive Markers of Response in Locally Advanced Breast Cancer, Treated With Bevacizumab Combined With Neoadjuvant Chemotherapy
Conditions
Interventions
Bevacizumab, docetaxel and doxorubicin followed by surgery
Locations
11
Spain
Hospital Obispo Polanco
Teruel, Aragon, Spain
Hospital Miguel Servet
Zaragoza, Aragon, Spain
Hospital General Yagüe
Burgos, Burgos, Spain
Hospital Universitario Marqués de Valdecilla
Santander, Cantabria, Spain
Hospital de Donosti
San Sebastián, Guipúzcoa, Spain
Onkologikoa
San Sebastián, Guipúzcoa, Spain
Start Date
October 1, 2009
Primary Completion Date
October 1, 2010
Completion Date
May 1, 2011
Last Updated
September 10, 2013
NCT07191730
NCT06312176
NCT06797635
NCT07003841
NCT07396766
NCT06443645
Lead Sponsor
Clinica Universidad de Navarra, Universidad de Navarra
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions